ANI Pharmaceuticals is building a leading Rare Disease company focused on Serving Patients, Improving Lives
ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension
2026-09-23
ANI Pharmaceuticals to Present at September Investor Conferences
2026-09-03
$74.83
+ 0.83 (1.12%)
Pricing delayed by 20 minutes
Last updated
2026-09-28 16:00:00